Trade name: Catheter Balloon Euphora. Technical Name: Catheters. ANVISA registration number: 10339190628. Class of risk: IV. affected model EUP1506X, EUP2015X, EUP22520X, EUP2530X, EUP3010X, EUP32512X, EUP3520X, EUP37525X, EUP1510X, EUP2020X, EUP22525X, EUP27506X, EUP3012X, EUP32515X, EUP3525X, EUP4006X, EUP1512X, EUP2025X, EUP2506X, EUP27510X, EUP3015X, EUP32520X, EUP3530X, EUP4010X , EUP1515X, EUP2030X, EUP2510X, EUP27512X, EUP3020X, EUP32525X, EUP37506X, EUP4012X, EUP1520X, EUP22506X, EUP2512X, EUP27515X, EUP3025X, EUP3506X, EUP37510X, EUP4015X, EUP2006X, EUP22510X, EUP2515X, EUP27520X, EUP3030X, EUP3510X, EUP37512X, EUP4020X, EUP2010X , EUP4020X, EUP2010X, EUP22512X, EUP2520X, EUP27525X, EUP32506X, EUP3512X, EUP37515X, EUP4025X, EUP2012X EUP22515X EUP2525X, EUP3006X, EUP32510X, EUP3515X, EUP37520X, EUP4030X, SLC1506X, SLC2015X, SLC22520X, SLC2530X, SLC3015X, SLC3512X, SLC4012X, SLC1510X, SLC2020X , SLC22525X, SLC2205XX, SLC2205XX, SLC2505XX, SLC2205XX, SLC2205XX, SLC2205XX, SLC2205XX, SLC2205XX, SLC2205XX, SLC2205XX, SLC2205XX , SLC2512X, SLC27525X, SLC32512X, SLC37512X, SLC4030X, SLC2006X, SLC22510X, SLC2515X, SLC3006X, SLC32515X, SLC37515X, SLC2010X, SLC22512X, SLC2520X, SLC3010X, SLC3506X, SLC37520X, SLC2012X, SLC22515X, SLC2525X, SLC3012X, SLC3510X, .. Number SLC4010X series affected: 212553130 to 213283557

Fabricante

  • Empresa matriz del fabricante (2017)
  • Comentario del fabricante
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    ANVSANVISA